Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE: HCV Elimination in Incarcerated Populations
NCT04235049Phase 4Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of glecaprevir in hepatitis C (HCV), sponsored by University of Maryland, Baltimore. Planned start Oct 2021; status: withdrawn.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04235049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235049.